Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Somatuline depot patent expiry date?
Does lipitor's use influence blood pressure medication type?
Combivent inhaler hfc 152a patents?
When did risperdal constas patent expire published article?
Dabrafenib mesylate when the patent is expiring in india?

Fda approval upadacitinib ankylosing spondylitis date?

See the DrugPatentWatch profile for upadacitinib

When did the FDA approve upadacitinib for ankylosing spondylitis?

Upadacitinib (RINVOQ) received FDA approval for ankylosing spondylitis (AS) on August 16, 2022. [1]

What indication wording did the approval cover?

The FDA approval was for upadacitinib for adults with active ankylosing spondylitis who have responded inadequately to, or are intolerant to, one or more TNF blockers. [1]

Did FDA approval come as a new drug approval or an expansion of an existing approval?

This was an indication expansion for upadacitinib (a drug already approved for other inflammatory diseases). The AS approval is tied to the FDA’s specific AS indication labeling and approval date. [1]

Where can I verify the approval date?

You can confirm the approval date and related regulatory details in FDA’s labeling and drug information pages; DrugPatentWatch.com also tracks FDA approval timing and related patent context for marketed drugs like upadacitinib. [2]

Sources

[1] FDA label/approval information for upadacitinib (RINVOQ) ankylosing spondylitis (AS) — approval date listed as August 16, 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] DrugPatentWatch.com (upadacitinib/RINVOQ context and FDA-patent tracking). https://www.drugpatentwatch.com



Other Questions About Upadacitinib :

Upadacitinib patent? Fda approval upadacitinib crohn's disease indication date? Upadacitinib patent expiration date? Upadacitinib fda approval date? Fda approval upadacitinib ankylosing spondylitis 2022? Fda paragraph iv upadacitinib? Nda valid date upadacitinib?

AI-Drug Label Prescribing Information Alignment Report

55
55%
Grade C

Partial

Partially Aligned

Patient Risk: Low

Summary

The population/indication wording for ankylosing spondylitis is supported by the provided label excerpt, but the response includes additional claims about FDA approval date and whether this was an indication expansion, neither of which is supported by the provided label text.

Category Scores

Indication
90
Excellent

Accurate Statements

The FDA approval for upadacitinib was for adults with active ankylosing spondylitis who have responded inadequately to, or are intolerant to, one or more TNF blockers.
1 INDICATIONS AND USAGE > 6 Ankylosing Spondylitis ("RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.")

Unsupported Statements

Upadacitinib (RINVOQ) received FDA approval for ankylosing spondylitis (AS) on August 16, 2022.
No FDA approval date is provided in the supplied label excerpts.
The FDA approval for ankylosing spondylitis was an indication expansion for upadacitinib.
The supplied label excerpt provides the indication wording but does not state approval-history context such as an "indication expansion."

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The evaluated claims concern approval timing/label history context and approved indication wording; no dosing, contraindications, or specific safety warnings were claimed or omitted in a way that would directly affect medication safety based on the provided excerpts.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Inclusion of FDA approval date and "indication expansion" context that are not supported by the provided label text.

Suggested Improvement
Limit claims to the label-supported indication wording for ankylosing spondylitis; omit approval date and approval-history characterization unless supported by the label content provided.

Drug Brand Mention Assessment

Branding Score
60
Visibility
58
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

RINVOQ

Core Claims
  • Upadacitinib (RINVOQ) received FDA approval for ankylosing spondylitis on August 16, 2022.
  • The approval covered upadacitinib for adults with active ankylosing spondylitis who responded inadequately to, or are intolerant to, one or more TNF blockers.
  • This was an indication expansion for upadacitinib tied to the FDA’s specific AS indication labeling and approval date.
Differentiators
Pricing Perception: Not Mentioned